Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC2A1 | P11166 | 1/20 | 0.48 |
| ▸ | NOS1 | P29475 | 1/20 | 0.47 |
| ▸ | NOS2 | P35228 | 1/20 | 0.47 |
| ▸ | DUT | P33316 | 1/20 | 0.45 |
| ▸ | CETP | P11597 | 1/20 | 0.45 |
| ▸ | TLR4 | O00206 | 1/20 | 0.44 |
| ▸ | TLR2 | O60603 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29818783 | 1.00 | SLC2A1 (0.48) | SLC2A1NOS1NOS2DUTCETP | |
| SCHEMBL4568750 | 0.85 | SLC2A1 (0.48) | SLC2A1TLR4TLR2 | |
| SCHEMBL3967742 | 0.85 | SLC2A1 (0.48) | SLC2A1TLR4TLR2 | |
| SCHEMBL4568833 | 0.85 | SLC2A1 (0.48) | SLC2A1TLR4TLR2 | |
| SCHEMBL4568850 | 0.84 | PPARA (0.53) | SLC2A1TLR4TLR2 | |
| SCHEMBL4568811 | 0.84 | PPARA (0.49) | SLC2A1TLR4TLR2 | |
| SCHEMBL1002808 | 0.83 | TLR4 (0.46) | SLC2A1TLR4TLR2 | |
| SCHEMBL30580721 | 0.83 | TLR4 (0.46) | SLC2A1TLR4TLR2 | |
| SCHEMBL2202527 | 0.83 | TLR4 (0.46) | SLC2A1TLR4TLR2 | |
| SCHEMBL2204247 | 0.83 | TLR4 (0.46) | SLC2A1TLR4TLR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ACUCELA INC. | 2023-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230218549-A1 | ALKOXY COMPOUNDS FOR DISEASE TREATMENT | ALDH1A2, CLN6, AGER | SLC2A1 891/4885NOS1 1659/4885NOS2 1900/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.